Inhibrx Biosciences, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
INBX Nasdaq 2836 inhibrx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Inhibrx Biosciences, Inc.

Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million - Jul 16th, 2026 7:00 am
Are You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choice - Jul 9th, 2026 10:00 am
Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma - Jun 15th, 2026 7:15 am
Inhibrx Reports First Quarter 2026 Financial Results - May 14th, 2026 2:02 pm
Inhibrx Biosciences (INBX) Announces Positive Interim Results From Phase 2 Portion of HexAgon Study - May 14th, 2026 10:52 am
Should Positive INBRX-106 Phase 2 Head and Neck Data Require Action From Inhibrx Biosciences (INBX) Investors? - May 12th, 2026 8:12 am
Merck Broadens KEYTRUDA Collaborations As Patent Expiry Pressure Builds - May 12th, 2026 4:07 am
Inhibrx Biosciences’ INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study - May 11th, 2026 10:08 am
This Biotech Stock Surges After Positive Cancer Trial Results. What to Know. - May 11th, 2026 9:51 am
Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy - May 11th, 2026 6:00 am
Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial - May 11th, 2026 4:00 am
Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC - May 8th, 2026 2:00 pm
Assessing Inhibrx Biosciences (INBX) Valuation After Ozekibart Data And Regulatory Momentum - May 1st, 2026 8:17 pm
Why Inhibrx Biosciences (INBX) Is Up 46.3% After New Ozekibart Colorectal Cancer Data And FDA Plans - Apr 26th, 2026 5:05 pm
Inhibrx Biosciences Highlights 20% ORR for Ozekibart Combo in Late-Line Colorectal Cancer - Apr 25th, 2026 5:12 am
INBX Stock Up on Upbeat Clinical Update From Colorectal Cancer Study - Apr 23rd, 2026 7:33 am
Top Midday Stories: GE Vernova Shares Gain on Strong Q1 Earnings, Guidance; Vertiv Lifts Guidance After Q1 EPS, Revenue Beats, Shares Fall - Apr 22nd, 2026 9:48 am
Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer - Apr 21st, 2026 2:05 pm
Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer - Apr 20th, 2026 3:03 pm
Coinbase downgraded, Deere upgraded: Wall Street's top analyst calls - Apr 8th, 2026 7:42 am